The Federal Trade Commission (FTC) and seven states have filed a contempt claim against Martin Shkreli, alleging that he has violated a lifetime ban from the pharmaceutical industry. The authorities are seeking a ruling to hold Shkreli accountable for his actions, which they argue breach the terms of the ban imposed on him.